Tharimmune, Inc. (NASDAQ:THAR – Get Free Report)’s share price crossed above its 50 day moving average during trading on Thursday. The stock has a 50 day moving average of $2.14 and traded as high as $2.21. Tharimmune shares last traded at $2.16, with a volume of 512,851 shares traded.
Tharimmune Stock Up 6.7%
The company has a 50-day simple moving average of $2.13 and a two-hundred day simple moving average of $2.97. The firm has a market cap of $77.72 million, a PE ratio of -0.52 and a beta of 1.43.
Tharimmune Company Profile
Tharimmune, Inc (NASDAQ:THAR) is a clinical-stage biotechnology company developing therapeutic candidates for immune-mediated and inflammatory diseases. The company focuses on conditions with significant unmet medical needs, including chronic pruritus and other disorders associated with dysregulated immune responses.
Tharimmune’s lead program, TH104, is an investigational buprenorphine-based therapy designed for the treatment of cholestatic pruritus associated with primary biliary cholangitis, a chronic liver disease.
Further Reading
- Five stocks we like better than Tharimmune
- Dutch Bros Gave Wall Street What It Wanted, So Why Did the Stock Crater?
- Astera Labs Just Crushed Earnings—So Why Are Analysts Cutting Price Targets?
- Sandisk Shares Are Oversold: Bargain or Value Trap?
- IonQ’s Record Revenue Includes a Big SkyWater Boost: Does That Change the Story?
Receive News & Ratings for Tharimmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tharimmune and related companies with MarketBeat.com's FREE daily email newsletter.
